


PRODUCT INFORMATION



Decamethonium (bromide)

Item No. 24907

CAS Registry No.: 541-22-0
Formal Name: N¹,N¹,N¹,N¹⁰,N¹⁰,N¹⁰-hexamethyl-1,10-decanediaminium, dibromide
MF: C₁₆H₃₈N₂ • 2Br
FW: 418.3
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Decamethonium (bromide) is supplied as a crystalline solid. A stock solution may be made by dissolving the decamethonium (bromide) in the solvent of choice, which should be purged with an inert gas. Decamethonium (bromide) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of decamethonium (bromide) in these solvents is approximately 33, 16, and 2 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of decamethonium (bromide) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of decamethonium (bromide) in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Decamethonium is a depolarizing neuromuscular blocking agent.¹ It is a partial agonist of muscle-type nicotinic acetylcholine receptors (nAChRs).² Decamethonium activates $\alpha 1\beta 1$ -containing adult mouse muscle-type nAChRs expressed in *X. laevis* oocytes with an EC₅₀ value of 40 μ M using voltage clamp electrophysiology. It is also a nondepolarizing antagonist of neuronal-type nAChRs, inhibiting mouse $\alpha 7$ -, $\alpha 3\beta 2$ -, $\alpha 3\beta 4$ -, and $\alpha 4\beta 2$ -containing receptors with IC₅₀ values of 7.4, 405, 28, and 59 μ M, respectively. Decamethonium is a competitive antagonist of $\alpha 4\beta 2$ -containing nAChRs expressed in SH-EP1 cells (IC₅₀ = 52 μ M for the human receptor).³ It also inhibits electric eel acetylcholinesterase (AChE) and blocks electrically-evoked tibialis muscle twitches in anesthetized cats with ED₉₅ values of 35 and 70 μ g/kg for cats under chloralose and ether anesthesia, respectively.^{1,4} Formulations containing decamethonium have been used to induce paralysis during anesthesia.

References

1. Paton, W.D. and Zaimis, E.J. *J. Physiol.* **112(3-4)**, 311-331 (1951).
2. Papke, R.L., Wecker, L., and Stitzel, J.A. *J. Pharmacol. Exp. Ther.* **333(2)**, 501-518 (2010).
3. Eaton, J.B., Peng, J.H., Schroeder, K.M., et al. *Mol. Pharmacol.* **64(6)**, 1283-1294 (2003).
4. Robaire, B. and Kato, G. *Mol. Pharmacol.* **11(6)**, 722-734 (1974).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM